Clinical value of Hemoglobin in Combination with Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as a Prognostic Factor in Advanced Lung Cancer
DOI:
https://doi.org/10.31185/wjps.382Keywords:
Haptoglobin, neutrophil-to-lymphocyte ratio, Lung cancer, PrognosticAbstract
The absence of effective prognostic factors for assessing the survival outlook of patients with lung cancer has not significant improvement. Thus, this study aims to investigate the potential of a combination of serum haptoglobin (Hp), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) in blood as reliable prognostic markers for lung cancer patients. There were 62 lung cancer patients (male and female) at advanced stage (stage III and IV) with age mean (65.25) years, and 62 healthy participants with age mean 64.27 years. The levels of some hematological parameters were estimated by a hematology analyzer. Heptoglobin level was evaluated in serum by ELISA technology. There was significant increase in mean of haptoglobin, NLR, and PLR in SCLC (3.43 ±0.16, 2.47±0.88, and 221 ±23.21, respectively) and NSCLC groups (3.64 ±0.09, 3.68±1.3, and 210.26±12.6, respectively) compared with control group. Haptoglobin, NRL and PRL did not differ significantly between SCLC and NSCLC. The results indicate that the mean haptoglobin, NLR, and PLR were significantly increased in lung cancer group in contrast to controls and also showed a positive association with the severity of the disease, where they increased in patients at stage IV and receiving chemotherapy for 2 months. This makes them possible markers for prognostic advanced lung cancer and predictive responses to chemotherapy in lung cancer patients.
References
H. Haryati and H. Diany, "Platelet-to-Lymphocyte Ratio (PLR) Profile and Neutrophil-to-Lymphocyte Ratio (NLR) in Lung Cancer Patients in Ulin General Hospital Banjarmasin 2017-2018," Berkala Kedokteran, vol. 16, no. 1, pp. 25-34, 2018.
Z. Q. Jasim and A.-H. A. Hadi, "Evaluation of some hematological criteria in lung cancer patients," International Journal of Health Sciences, vol. 6, no. S6, pp. 2801-2813, 2022.
Iraqi Cancer Board (ICB), "Iraq Cancer Registry for 2018 report," Ministry of Health and Environment, Iraq, 2018.
G. Wu et al., "Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non‐small cell lung cancer patients," Thoracic cancer, vol. 6, no. 3, pp. 275-287, 2015.
S. M. Kang et al., "The Haptoglobin β chain as a supportive biomarker for human lung cancers," Molecular BioSystems, vol. 7, no. 4, pp. 1167-1175, 2011.
M. K. Tveitarås et al., "Protein expression profiling of plasma and lungs at different stages of metastatic development in a human triple negative breast cancer xenograft model," PLoS One, vol. 14, no. 5, p. e0215909, 2019.
A. Shah et al., "Differential serum level of specific haptoglobin isoforms in small cell lung cancer," Current proteomics, vol. 7, no. 1, pp. 49-56, 2010.
B. Wang et al., "Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer," Asian Pacific journal of cancer prevention, vol. 15, no. 22, pp. 9611-9614, 2014.
T. Chen et al., "Disease-specific haptoglobin-β chain N-glycosylation as biomarker to differentiate non-small cell lung cancer from benign lung diseases," Journal of Cancer, vol. 10, no. 23, pp. 5628, 2019.
National Institutes of Health (NIH), "National Cancer Institute-NCI Dictionary of Cancer," 2018.
L. Rojko et al., "Longitudinal analysis of complete blood count parameters in advanced‐stage lung cancer patients," Thoracic Cancer, vol. 11, no. 11, pp. 3193-3204, 2020.
P. Goldstraw, K. Chansky, and J. Crowley, "The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer," J Thorac Oncol, vol. 11, pp. 39–51, 2016.
F. Wu et al., "Prognostic value of baseline hemoglobin‐to‐red blood cell distribution width ratio in small cell lung cancer: A retrospective analysis," Thoracic Cancer, vol. 11, no. 4, pp. 888-897, 2020.
X. Ke et al., "Hypoxia modifies the polarization of macrophages and their inflammatory microenvironment, and inhibits malignant behavior in cancer cells," Oncology Letters, vol. 18, no. 6, pp. 5871-5878, 2019.
F. D. Celik et al., "The Significance of Hemogram Parameters for Diagnosis, Prognosis and Treatment of Lung Cancer," Eurasian Journal of Medical Investigation, vol. 5, no. 2, p. 159, 2021.
J. Liu et al., "Systemic immune‐inflammation index, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio can predict clinical outcomes in patients with metastatic non‐small-cell lung cancer treated with nivolumab," Journal of Clinical Laboratory Analysis, vol. 33, no. 8, pp. 1-8, 2019.
F. Karadeniz, Y. Karadeniz, and E. Altuntaş, "Systemic immune-inflammation index, and neutrophil to-lymphocyte and platelet-to-lymphocyte ratios can predict clinical outcomes in patients with acute coronary syndrome," Cardiovasc J Afr, vol. 34, pp. 1-7, 2023.
S. R. Thottuvelil et al., "Comparison of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) as marker of adverse prognosis in patients with infective endocarditis," Indian Heart Journal, vol. 75, no. 6, pp. 465-468, 2023.
J. Y. Y. Wong et al., "White blood cell count and risk of incident lung cancer in the UK Biobank," JNCI Cancer Spectrum, vol. 4, no. 2, pp. 1-9, 2019.
H. Zhang et al., "Serum immunoinflammatory-related protein complexes as personalized biomarkers for monitoring disease progression and response to treatment in lung cancer patients," Clinica Chimica Acta, vol. 533, pp. 53-62, 2022.
J. Lu et al., "High serum haptoglobin level is associated with tumor progression and predicts poor prognosis in non-small cell lung cancer," Oncotarget, vol. 7, no. 27, pp. 41758, 2016.
L. F. Hoagland et al., "Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer," Cancer, vol. 110, pp. 2260-2268, 2007.
X. Zhu et al., "Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in blood to distinguish lung cancer patients from healthy subjects," Disease Markers, 2020.
M. Ye et al., "Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predict severity and prognosis of lower limb arteriosclerosis obliterans," Annals of vascular surgery, vol. 64, pp. 221-227, 2020.
H. Zhao et al., "Preoperative neutrophil-to-lymphocyte ratio was a predictor of overall survival in small renal cell carcinoma: an analysis of 384 consecutive patients," BioMed Research International, vol. 2020, Article ID 8051210, 2020.
G. A. Siregar and D. Irwansyah, "Comparison of platelet to lymphocyte ratio between degrees of the Barcelona clinic liver cancer on hepatocellular carcinoma patients at Haji Adam Malik General Hospital," Open Access Macedonian Journal of Medical Sciences, vol. 7, no. 20, pp. 3451-3454, 2019.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Noor Hanoush
This work is licensed under a Creative Commons Attribution 4.0 International License.
